Endocannabinoid System: CB1, CB2, and the Limits of Research

What are the components of the endocannabinoid system?

The endocannabinoid system, abbreviated ECS, is a biological signalling system. Its known signalling molecules include anandamide, also referred to as AEA, and 2-arachidonoylglycerol, abbreviated 2-AG. The prefix “endo” means endogenous. These substances are produced by the body and are not equivalent to the cannabinoids found in a cannabis flower.

The principal receptors include CB1 and CB2. Enzymes are involved in the production and breakdown of the signalling molecules; frequently cited examples of degradation pathways are FAAH and MAGL. A description involving only two receptors is helpful as an introduction, but simplifies the broader network of related signalling processes.

The ECS is involved in a range of physiological functions. It does not follow from this that any modification of the system remedies a disease. The effect depends on which tissue, which signalling pathway, and which condition are being examined. An overly simple picture of an “balance switch” can obscure this relationship.

As an overview, the same academic paper already used in the original article serves as a reference: Lu and Mackie, An Introduction to the Endogenous Cannabinoid System. It is a review article and is labeled as such here, not as a clinical efficacy study of a product.

What do CB1 and CB2 mean?

CB1 and CB2 are designations for distinct cannabinoid receptors. CB1 is often explained in terms of the nervous system and CB2 in terms of immune processes. This distinction is useful as a starting point, but should not be simplified into a rigid map on which each receptor occurs exclusively in a single organ.

A binding assay first examines whether a substance interacts with a receptor-binding site under the given conditions. A functional assay asks whether a particular signal is altered. These two questions are not identical. Nor can the magnitude of a signal be directly translated into the magnitude of a perceived effect.

The following overview explains the most important terms. It does not describe personal treatment effects and is not a ranking of useful or harmful molecules. Further studies would be required for a clinical assessment.

The meaning of these terms depends on the system under investigation. A glossary should therefore always additionally specify which endpoint was actually measured.

How do endogenous and plant-derived cannabinoids differ?

Endocannabinoids are produced and broken down within a temporally and spatially regulated context. THC from a consumed product enters the body by a different route. The fact that both can interact with related receptor systems does not make their exposure identical.

THC and CBD should likewise not be presented as equivalent keys to the same locks. Their pharmacology differs. A blanket claim that CBD reliably neutralizes THC or prevents its unwanted effects is therefore not appropriate.

To assess a combination, the composition, dose, route of administration, and outcome must be stated precisely. A product name such as “balanced” is no substitute for these details. Equally, the mere presence of CBD or terpenes does not indicate whether the product is better tolerated by a particular person.

What can be said about terpenes and CB2?

Why is ‘155 nanomolar’ not a universal effect threshold?

In Figure 2, the Kᵢ value calculated from a sigmoidal fit is 155 ± 4 nM, whereas the Hill plot gives 780 ± 12 nM. The authors discuss poor water solubility and aggregation; the supplement also describes an influence of the albumin content in the binding buffer. Such an inhibition constant characterizes the particular binding experiment. It is neither a dose nor the concentration at which a person begins to benefit.

What connects the experiments, and where do their conclusions end?

The cell model examined cAMP and calcium responses. Paw swelling was measured in male mice after oral administration; comparison with CB2-deficient animals supports receptor involvement. The dose–response relationship was not consistently monotonic, and pretreatment times differed between dose groups. These findings do not establish that ‘more substance means more benefit’.

How do later, divergent findings fit in?

Santiago examined a potassium-channel-dependent membrane response in AtT20 cells. Finlay used, among other models, HEK cells with a cAMP biosensor and found no corresponding functional activation; the CB2 binding experiment showed only limited displacement. Both papers are discussed in the terpene article with original sources.

Direct comparison of the methods reveals differences in cellular background, receptor construct, signalling readout and experimental medium. For example, Gertsch used 0.5 mg/ml albumin in the binding buffer, whereas Finlay used 2 mg/ml. These differences offer possible explanations but do not experimentally resolve the discrepancy. That would require a targeted comparison under matched conditions.

How reliable is extrapolation to humans?

Human blood samples do not turn a laboratory experiment into a treatment of people. Similarly, an acute paw oedema model tests neither chronic disease nor inhalation of cannabis flower. Limited transferability remains even when an individual receptor mechanism is plausible.

Gertsch reports at least nine mice per group, DFG funding and no declared conflicts of interest. Randomisation or blinded assessment of the animals is not described in the reviewed main text or supplement. Here, ‘not reported’ limits transparency; it does not prove that the procedure was omitted. Locations: Figures 2, 4 and 5; Materials and Methods; SI Materials and Methods.

The later studies by Santiago and Finlay examine defined receptor models with different functional endpoints. Their findings are explained in the terpene article with study boxes. They must not be reinterpreted as clinical comparisons between full-spectrum products and isolated cannabinoids.

A preclinical observation can support an interesting hypothesis. To turn it into a treatment claim, however, it would first need to be established whether relevant concentrations are achieved in humans, what benefit actually results, and what adverse effects occur. A peppery aroma answers none of these questions.

Why is a receptor explanation not a safety guarantee?

The earlier claim that important bodily functions remain unimpaired even at high THC intake was too far-reaching. A general absence of harm cannot be inferred from the distribution of individual receptors. Nor does a distinction from another substance mean that cannabis cannot have serious adverse effects.

The US health authority NIDA describes, among other things, acute anxiety, confusion and impairment, as well as increased risks at high THC quantities or high product potency. The current NIDA overview of cannabis is cited here as a separate medical supplementary source; this safety assessment does not derive from the terpene studies.

The absence of smoke and a pleasant aroma do not cancel pharmacological risks either. The right question is therefore not only whether a substance was combusted, but also what compounds and quantities are inhaled and what individual factors are involved.

Why cannot the ECS be controlled via a temperature table?

A vaporizer initially alters the heating and release of the source material. Between the setting on the display and an effect in the body lie several steps: chemical composition, transition into the aerosol, losses within the device, inhalation, uptake, and processing in the body.

None of these steps is fully described by a boiling-point figure alone. A particular setting therefore does not selectively activate a receptor. Equally, a temperature range in which a device produces aerosol is not scientific evidence for a specific mood, relaxation, or medical effect.

The article on cannabinoid boiling points explains the physical side. The piece on decarboxylation separates chemical conversion from release. This distinction prevents technical terminology from inadvertently becoming therapeutic instructions.

How should one evaluate medical claims about the ECS?

Check first whether the source actually studied humans with the condition in question. A cell line, an animal model, and a patient group represent different levels of evidence. Next, the preparation studied must match the claim being made: a licensed medicinal product is not interchangeable with every cannabis product.

Also important are the comparator group, duration, and endpoint. A short-term change in a laboratory value answers a different question from a perceptible improvement in everyday life. Likewise, the frequency of adverse effects and withdrawals must be taken into account.

A clear study description therefore does not report only the positive result. It also explains what was not measured, what uncertainty remains, and whether the conclusion extends beyond the population studied. This protects against an apparently plausible chain leading from a receptor to a therapeutic promise.

Frequently asked questions about the ECS

Source status and corrections

Updated on 10 September 2026. The basic overview by Lu and Mackie and the NIDA safety overview are additional sources outside the terpene register. Receptor studies are contextualised through the directly linked methods sections. Gertsch et al. were reviewed in full, including the methodological supplement, and compared with the assays of Santiago and Finlay; findings obtained with different methods remain clearly distinguished.

Removed were the absolute safety assurance for high THC intake, blanket disease claims derived from CB2 activity, and the attribution of individual receptor effects to vaporizer temperatures. This article is a scientific introduction, not an individual diagnosis or treatment recommendation.

Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E. 2023. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ (Clinical research ed.). DOI: 10.1136/bmj-2022-072348 · PMID 37648266 · PMC10466434

Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. 2016. Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clinical chemistry. DOI: 10.1373/clinchem.2016.263475 · PMID 27899456

Poyatos L, Pérez-Acevedo AP, Papaseit E, Pérez-Mañá C, Martin S, Hladun O, Siles A, Torrens M, Busardo FP, Farré M. 2020. Oral Administration of Cannabis and Δ-9-tetrahydrocannabinol (THC) Preparations: A Systematic Review. Medicina (Kaunas, Lithuania). DOI: 10.3390/medicina56060309 · PMID 32585912 · PMC7353904

Lanz C, Mattsson J, Soydaner U, Brenneisen R. 2016. Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PloS one. DOI: 10.1371/journal.pone.0147286 · PMID 26784441 · PMC4718604